Nicole Johnston, Country Therapy Area Head, Immunology for Novartis Australia and New Zealand, said the company is assessing the viability of a reimbursement submission while supporting access through private pathways in the interim.
Rhapsido approved in Australia as first oral targeted option for chronic spontaneous urticaria
June 18, 2026 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
New AusBiotech membership aims to help Australia’s early-stage life sciences founders thrive
July 30, 2026 - - Latest News -
AI will likely grow the HTA 'industrial complex', but it can also democratise the institution
July 30, 2026 - - Latest News -
CSL begins clinical trials to test higher-yield plasma manufacturing
July 30, 2026 - - Latest News -
AbbVie records 13-year streak as 'A Great Place to Work'
July 29, 2026 - - Latest News -
Helping to build Australia’s life sciences future at Brisbane’s innovation junction
July 29, 2026 - - Latest News -
AFT Pharmaceuticals sees significant opportunity in a diverse R&D pipeline
July 28, 2026 - - Latest News -
Australians with rare diseases still waiting too long for access to treatments
July 28, 2026 - - Latest News

